ACEPHAP, partners conduct IVON PP Trial Close-out Ceremony and Dissemination of Findings Meeting
The Africa Centre of Excellence for Population Health and Policy (ACEPHAP) joined partners in celebrating the successful completion of the IVON-PP Trial, a groundbreaking maternal health study supported by the Bill & Melinda Gates Foundation and a major step forward for women’s health in Nigeria.
The Director of the center, Professor Hadiza Galadanci, was represented by Dr. Abdullahi Yahaya Salihi at the event after two and a half years of research across Lagos, Kano, Kwara, and Rivers States.
The study, titled “Intravenous Ferric Carboxymaltose versus Oral Ferrous Sulphate for the Treatment of Moderate to Severe Postpartum Anaemia in Nigerian Women (IVON-PP): An Open-Label Randomized Controlled Trial and Implementation Study),” especially revealed that intravenous ferric carboxymaltose (FCM) is more effective, safe, and faster in treating postpartum anaemia compared to traditional oral iron therapy — a discovery that could transform maternal care across Nigeria and beyond.
The evidence revealed by the study provides a strong basis for improving maternal health interventions and policies not only in Nigeria, but also across sub-Saharan Africa. The session ended with a commitment to more future collaborations to improve maternal health in Nigeria.
You can join the conversation on:
- Instagram: @acephap_buk
- LinkedIn: @acephap
- Facebook: @acephap
- X/Twitter: @acephap_buk
